Researchers at Stanford University have developed a method and composition of immunomodulatory compounds that prevent and reverse T cell exhaustion, improving on existing CAR T cell therapies.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.